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Summary
The production of single enantiomers of drug intermediates has become increasingly
important in the pharmaceutical industry. Chiral intermediates and fine chemicals are in
high demand from both the pharmaceutical and agrochemical industries for the prepara-
tion of bulk drug substances and agricultural products. The enormous potential of micro-
organisms and enzymes for the transformation of synthetic chemicals with high chemo-,
regio- and enantioselectivities has been demonstrated. In this article, biocatalytic processes
are described for the synthesis of chiral pharmaceutical intermediates.
Key words: biocatalysis, chiral intermediates, antiviral, anticancer, antihypertensive, anti-in-
fective, receptor agonists/antagonists, enantioselective enzymatic de-protection
Introduction
The production of single enantiomers of chiral inter-
mediates has become increasingly important in the
pharmaceutical industry (1). Single enantiomers can be
produced by chemical or chemo-enzymatic synthesis.
The advantage of biocatalysis over chemical synthesis is
that enzyme-catalyzed reactions are often highly enan-
tioselective and regioselective. They can be carried out
at ambient temperature and atmospheric pressure, thus
avoiding the use of more extreme conditions that can
cause problems with isomerization, racemization, epime-
rization and rearrangement. Microbial cells and enzymes
derived from them can be immobilized and reused for
many cycles, and enzymes can be over-expressed to
make biocatalytic processes economically efficient. A
number of review articles (2–8) on the use of enzymes in
organic synthesis have been published. The current re-
view provides examples of the use of enzymes for the
synthesis of single enantiomers of key intermediates
used in the preparation of pharmaceuticals.
Antiviral Agents
Atazanavir
An essential step in the life cycle of human immu-
nodeficiency virus (HIV-1) is the proteolytic processing
of its precursor proteins. This processing is accomplished
by HIV-1 protease, a virally encoded enzyme. Inhibition
of HIV-1 protease arrests the replication of HIV in vitro.
Thus, HIV-1 protease is an attractive target for chemo-
therapeutic intervention (9,10). Atazanavir 1 Scheme 1A
is an acyclic aza-peptidomimetic that is a potent HIV
protease inhibitor (11,12). The original process was
utilized for small-scale preparation of Atazanavir to
support initial development (13) and subsequently an
improved process for the large-scale synthesis of Ata-
zanavir was developed (14).
An alternative biocatalytic process was developed for
the preparation of a key chiral intermediate required for
the synthesis of Atazanavir (15). The diastereoselective
microbial reduction of (1S)-3-chloro-2-oxo-1-(phenylme-
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thyl)propylcarbamic acid, 1,1-dimethyl-ethyl ester (S)-2
to homochiral chlorohydrin (1S,2R)-3-chloro-2-oxo-1-
-(phenylmethyl)propylcarbamic acid, 1,1-dimethyl-ethyl
ester (1S,2R)-3, has been demonstrated Scheme 1B.
Among microbial cultures evaluated, Rhodococcus, Brevi-
bacterium and Hansenula strains reduced (S)-2 to (1S,2R)-3.
Three strains of Rhodococcus gave >90 % yield with a
diastereomeric purity of >98 % and enantiomeric excess
(e.e.) of 99.4 %. Rhodococcus erythropolis SC 13845 and
Rhodococcus sp. 16002 were grown in a 25-L fermentor
for 48 h. The cells were collected and suspended in 70
mM potassium phosphate buffer (pH=7.0), and the re-
sulting cell-suspensions were used to carry out the two-
-stage process for biotransformation of (S)-2. A reaction
yield of >92 %, diastereomeric purities of >98 % and en-
antiomeric excesses of 99.3–99.4 % for alcohol (1S,2R)-3
were obtained. An efficient single-stage fermentation-
-biotransformation process was developed for the reduc-
tion of ketone (S)-2 with cells of Rhodococcus erythropolis
SC 13845. A reaction yield of 95 %, diastereomeric pu-
rity of 98.2 % and enantiomeric excess of 99.4 % for
(1S,2R)-3 were obtained.
Synthesis of Atazanavir also required the (S)-ter-
tiary leucine 5 Scheme 1C. An enzymatic process was
developed for the synthesis 5. Enzymatic reductive ami-
nation of keto acid 4 to amino acid 5 by leucine dehy-
drogenase from Thermoactinimyces intermedius has been
demonstrated. Leucine dehydrogenase from T. interme-
dius was cloned and over-expressed in Escherichia coli.
The reaction required ammonia and NADH as a cofac-
tor. NAD produced during the reaction was regenerated
back to NADH using formate dehydrogenase from Pi-
chia pastoris. Formate dehydrogenase from P. pastoris
was also cloned and over-expressed in Escherichia coli. A
reaction yield of >95 % and enantiomeric excess of >99.5
% were obtained for 5 at 100 g/L of substrate input (R.
Hanson, S. Goldberg, R. Patel, unpublished results).
BMS-186318
Barrish et al. (16) reported the discovery of a new
class of selective HIV protease inhibitors that incorpo-
rate a C-2 symmetric aminodiol core as a key structural
feature. Members of this class, particularly compound 6
Scheme 2, display potent anti-HIV activity in cell cul-
ture. The diastereoselective microbial reduction of (1S)-
-3-chloro-2-oxo-1-(phenylmethyl)-propylcarbamic acid,
1,1-dimethyl-ethyl ester (S)-2 to (1S,2S)-3-chloro-2-hy-
droxy-1-(phenylmethyl)propylcarbamic acid, 1,1-dime-
thyl-ethyl ester (1S,2S)-7, a key intermediate in the total
chemical synthesis of BMS-186318, has been demon-
strated (17). Among 100 microorganisms screened for
the reduction, the two best cultures, Streptomyces nodosus
SC 13149 and Mortierella ramanniana SC 13850, were
used to convert (S)-2 to (1S,2S)-7 in 60-65 % reaction
yields, 99.9 % e.e.’s and >99 % diastereomeric purities.
An efficient single-stage fermentation-biotransformation
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Scheme 1. Synthesis of chiral intermediates for antiviral agent 1: (A) Enantioselective enzymatic reduction of (1S)3-chloro-2-oxo-
-1(phenylmethyl)propylcarbamic acid 1,1-dimethyl-ethyl ester 2 to the corresponding (1S,2R) 3 by Rhodococcus erythropolis SC 13845.
(B) Synthesis of chiral intermediates for antiviral agent 1: enzymatic reductive amination of keto acid 4 to (S)-t-leucine 5 by leucine
dehydrogenase
Boc – t-butylcarbonyl group
process was developed using cells of S. nodosus SC
13149. A reaction yield of 80 %, a diastereomeric purity
of >99 % and an e.e. of 99.8 % were obtained for (1S,
2S)-7 at 10 g/L of substrate input.
Indinavir
Cis-(1S,2R)-indandiol 9 or trans-(1R,2R)-indandiol 9
Scheme 3A are both potential precursors to cis-(1S,
2R)-1-aminoindan-2-ol 12, a key chiral synthon for Cri-
xivan (Indinavir) 13 Scheme 3B, an HIV protease in-
hibitor. Enrichment and isolation of microbial cultures
yielded two strains, Rhodococcus sp. B 264-1 (MB 5655)
and I-24 (MA 7205), capable of biotransforming indene 8
to cis-(1S,2R)-indandiol and trans-(1R,2R)-indandiol re-
spectively (18). Isolate MB 5655 was found to have a to-
luene dioxygenase, while isolate MA 7205 was found to
harbor both toluene and naphthalene dioxygenases as
well as a naphthalene monooxygenase that catalyzes the



























Scheme 2. Synthesis of chiral intermediates for HIV-protease inhibitor 6: enantioselective enzymatic reduction of (1S)-3-chloro-
-2-oxo-1(phenylmethyl)propylcarbamic acid, 1,1-dimethyl-ethyl ester 2 to the corresponding (1S,2S) 7 by Streptomyces nodosus SC
13149


























































Scheme 3. Synthesis of chiral intermediates for Crixivan 13: (A) Microbial oxygenation of indene 8 to cis-indandiol 9 and trans-
-indandiol 9. (C) Resolution of racemic indene oxide 14 to (1S,2R)-indene oxide 14 by epoxide hydrolase from Diplodia gossipina
above biotransformation. When scaled up in a 14-L fer-
mentor, MB5655 produced up to 2.0 g/L of cis-(1S,2R)-
-indandiol 9 with e.e. >99 %. Rhodococcus sp. MA 7205
cultivated under similar conditions produced up to 1.4
g/L of trans-(1R,2R)-indandiol 9 with e.e. >98 %. Process
development studies yielded titers of greater than 4.0
g/L of trans-(1R,2R)-indandiol 9 (19). A metabolic engi-
neering approach (20) and a directed evolution tech-
nique (21) were evaluated to avoid side reactions, block
degradative pathways and enhance the key reaction to
convert indene to cis-amino indanol or cis-indandiol.
Multi-parameter flow cytometry was employed for
the measurement of indene toxicity to the strain. Con-
centrations of indene up to 0.25 g/L (0.037 g (indene)/g
(dry cell)) in batch bioconversions did not influence cell
physiology. Using this information, a single-phase in-
dene fed-batch bioconversion was carried out. Cytoplas-
mic membrane integrity and membrane polarization of
a large number of cells were measured during biocon-
versions and compared to a control in order to assess
any toxic effects of indene feeding. Indene supply at a
rate of 0.1 g L–1h–1 was feasible without any deleterious
effects. Cis-(1S,2R)-indandiol 9 production rates were
enhanced from 20 up to 200 mg L–1h–1, in a silicone oil
two-liquid-phase system, by a combination of suitable
indene feeding rates in the stationary phase and operat-
ing with a high biomass concentration (22).
In an alternate process, an epoxide hydrolase from
Diplodia gossipina was used for the resolution of racemic
indene oxide 14 Scheme 3C. The desired enantiomer
(1S,2R)-indene oxide 14, a chiral intermediate for Crixi-
van, was obtained in 14 % yield and >99.9 % e.e.
Lobucavir
Lobucavir 20 Scheme 4 is a cyclobutyl guanine nu-
cleoside analog that is potentially useful as an antiviral
agent for the treatment of herpes virus and hepatitis B
(23). The lobucavir pro-drug L-valine 1S,2R,3R)-3-(2-
-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymeth-
yl)cyclobutylmethyl ester monohydrochloride 22, in
which one of the two hydroxyls is coupled to valine, has
also been considered for development. Regioselective
aminoacylation was difficult to achieve by chemical pro-
cedures but appeared to be suitable for an enzymatic
approach (24). Synthesis of the lobucavir pro-drug 22 re-
quired regioselective coupling of one of the two hydro-
xyl groups of lobucavir with valine. Enzymatic proces-
ses were developed for the aminoacylation of either
hydroxyl group of lobucavir (24). The selective hydroly-
sis of N,N’-bis(phenylmethoxy)carbonylbisL-valine,
O,O’-(1S,2R,3R)-3-(2-amino-6-oxo-1H-purin-9-yl)cyclo-
butan-1,2-diylmethyl ester 16 Scheme 4 was accom-
plished with lipase M (Amano Enzyme Company) to
yield 18 in 83 % yield. When bisvaline,O,O’-(1S,2R,
3R)-3-(2-amino-6-oxo-1H-purin-9-yl)cyclobutan-1,2-diyl
methyl ester 17 dihydrochloride was hydrolysed with li-
pase from Candida cylindraceae, 19 was obtained in 87 %
yield. Compound 21, the final intermediate for the lobu-
cavir pro-drug 22, could be obtained by transesterifi-
cation of lobucavir using ChiroCLECTM BL from Altus
Company (61 % yield) or more selectively by using the
lipase from Pseudomonas cepacia immobilized on Accurell
polypropylene (84 % yield).
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Scheme 4. Synthesis of chiral intermediates for the lobucavir pro-drug 22: (A) Regioselective enzymatic hydrolysis of 16 and 17.
(B) Regioselective enzymatic aminoacylation of lobucavir 20
Cbz – carbobenzyloxy group
Ribavirin pro-drug
Ribavirin 23 Scheme 5 is an antiviral agent used in
combination with -2 interferon to treat hepatitis C
(25–27). Although this therapy is effective against hepa-
titis C virus, it has several side effects (28,29). To improve
the pharmacokinetics profile and reduce side effects,
ribavirin pro-drug was considered for development. In a
series of preclinical evaluations, the alanine ester of ri-
bavirin 24 Scheme 5 showed improved bioavalibility
and reduced side effects. The synthesis of 24 required
the acylation of unprotected ribavirin. Chemical acyla-
tion gave a mixture of mono-, di- and triacylated prod-
ucts. An enzymatic process was developed for the regio-
selective acylation of ribavirin 23 with oxome ester of
L-carbobenzyloxy(cbz)-alanine 25 to give the desired 26
using Novozym 435 (Candida antarctica lipase B). The
chemical de-protection of 26 gave 24. In a preparative-
-scale process, the coupling of 27 with acetone oxime in
the presence of di-t-butyl dicarbonate in THF was car-
ried out giving 25 in greater than 96 % yield. At the end
of the reaction, the reaction mixture was diluted three-
-fold with THF and ribavirin was added and the acyla-
tion was initiated by the addition of lipase. Following
24-h reaction at 60 °C, the product 26 was isolated in 85
% yield (30).
Anti-Infective Drugs
Microbial hydroxylation of pleuromutilin or mutilin
Pleuromutilin 28 Scheme 6 is an antibiotic from
Pleurotus or Clitopilus basidiomycete strains that kills
mainly gram-positive bacteria and mycoplasms. A more
active semi-synthetic analogue, tiamulin, has been de-
veloped for the treatment of infections of animals and
poultry and has been shown to bind to prokaryotic ribo-
somes and inhibit protein synthesis (31). Metabolism of
pleuromutilin derivatives results in hydroxylation by
microsomal cytochrome P-450 at the 2- or 8-position and
inactivates the antibiotics (32). Modification of the 8-po-
sition of pleuromutilin and analogues is of interest as a
mean of preventing the metabolic hydroxylation. Micro-
bial hydroxylation of pleuromutilin 28 or mutilin 30
would provide a functional group at this position to al-
low further modification at this site to avoid metabolic
hydroxylation. The target analogues would maintain the
biological activity of the parent compounds but would
not be susceptible to metabolic inactivation.
Biotransformation of mutilin and pleuromutilin by
microbial cultures has been investigated to provide a
source of 8-hydroxymutilin or 8-hydroxypleuromutilin
(33). Streptomyces griseus strains SC 1754 and SC 13971
(ATCC 13273) hydroxylated mutilin to (2S)-hydroxymu-
tilin 31, (8S)-hydroxymutilin 32 and (7S)-hydroxymutilin
33 Scheme 6. Cunninghamella echinulata SC 16162 (NRRL
3655) gave (2S)-hydroxymutilin 31 or (2R)-hydroxyple-
uromutilin 29 from biotransformation of mutilin or ple-
uromutilin, respectively. The biotransformation of muti-
lin by the S. griseus strain SC 1754 was scaled up in 15-,
60-, and 100-L fermentations to produce a total of 49 g
of (8S)-hydroxymutilin (BMS-303786), 17 g of (7S)-hy-
droxymutilin (BMS-303789) and 13 g of (2S)-hydroxy-
mutilin (BMS-303782) from 162 g of mutilin (33).
A C-8 ketopleuromutilin 34 derivative has been syn-
thesized from the biotransformation product 8-(S)-hydro-
xymutilin (34). A key step in the process was the selec-
tive oxidation at C-8 of 8-hydroxymutilin using tetra-
propylammonium perruthenate. The presence of the C-8
keto group gave an interesting intramolecular chemistry
to afford a compound with a novel pleuromutilin-de-
rived 35 ring system, which was achieved by acid-cata-
lyzed conversion of C-8 ketopleuromutilin.
Anticancer Agents
Paclitaxel
Among the antimitotic agents, paclitaxel 36 Scheme
7, a complex, polycyclic diterpene, exhibits a unique
mode of action on microtubule proteins responsible for




























































Scheme 5. Synthesis of chiral intermediates ribavirin pro-drug 24: regioselective enzymatic acylation of ribavirin 23 with oxome es-
ter of L-carbobenzyloxy(cbz)-alanine 25 to give desired product 26 using Novozym 435
the formation of the spindle during cell division (35–39).
Paclitaxel inhibits the depolymerization process of mi-
crotubulin (39,40). Various types of cancers have been
treated with paclitaxel and the results in treatment of
ovarian cancer and metastatic breast cancer are very
promising. Paclitaxel was originally isolated from the
bark of the yew, Taxus brevifolia, and has also been
found in other Taxus species in relatively low yield.
Paclitaxel was obtained from T. brevifolia bark in 0.07 %
yield and it required cumbersome purification from the
other related taxanes. It is estimated that about 9000 kg
of yew bark (the equivalent of about 3000 trees) are
needed to produce 1 kg of purified paclitaxel (41,42).
The development of a semi-synthetic process for the
production of paclitaxel from baccatin III 37 (paclitaxel
without the C-13 side-chain) or 10-deacetyl-baccatin III
38 (10-DAB, paclitaxel without the C-13 side-chain and
the C-10 acetate) and C-13 paclitaxel side-chain 40 or 44
Scheme 7 is a very promising approach. Baccatin III
and 10-DAB can be derived from renewable resources
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Scheme 7. Semisynthesis of paclitaxel 36, an anticancer agent. Coupling of baccatin III 37 and C-13 paclitaxel side-chain synthons 40
or 44
such as extracts of needles, shoots and young Taxus cul-
tivars (43). Thus the preparation of paclitaxel by semi-
-synthetic process eliminates cutting down the large
yew trees.
By using selective enrichment techniques, two strains
of Nocardioides were isolated from soil samples that con-
tained novel enzymes C-13 taxolase, C-10 deacetylase
and C-7 xylosidase (44–46). The extracellular C-13 taxo-
lase derived from the filtrate of the fermentation broth
of Nocardioides albus SC 13911 Scheme 8A catalyzed the
cleavage of C-13 side-chain from paclitaxel and related
taxanes such as taxol C, cephalomannine, 7--xylosylta-
xol, 7--xylosyl-10-deacetyltaxol, and 10-deacetyltaxol
Scheme 8A. The intracellular C-10 deacetylase derived
from the fermentation of Nocardioides luteus SC 13912
Scheme 8B catalyzed the cleavage of C-10 acetate from
paclitaxel, related taxanes and baccatin III to yield
10-DAB. The C-7 xylosidase derived from the fermenta-
tion of Moraxella sp. Scheme 8C catalyzed the cleavage
of C-7 xylosyl group from various taxanes. Fermentation
processes were developed for growth of N. albus SC
13911, N. luteus SC 13912 and Moraxella sp. to produce
C-13 taxolase, C-10 deacetylase and C-7 xylosidase, re-
spectively, in 5000-L batches, and a bioconversion pro-
cess was demonstrated for the conversion of paclitaxel
and related taxanes in extracts of Taxus cultivars to a
single compound 10-DAB using both enzymes. In the
bioconversion process, ethanolic extracts of the whole
young plant of five different cultivars of Taxus were first
treated with a crude preparation of the C-13 taxolase to
give complete conversion of measured taxanes to bac-
catin III and 10-DAB in 6 hours. Whole cells of Nocar-
dioides luteus SC 13192 were then added to the reaction
mixture to give complete conversion of baccatin III to
10-DAB. The concentration of 10-DAB was increased by
6- to 24-fold in the extracts treated with enzymes. The
bioconversion process was also applied to extracts of the
bark of T. bravifolia to give a 12-fold increase in 10-DAB
concentration. The enhancement of 10-DAB concentra-
tion in yew extracts was potentially useful in increasing
the amount of this key precursor for the paclitaxel semi-
-synthetic process using renewable resources.
Another key step in the paclitaxel semi-synthetic
process is the preparation of chiral C-13 paclitaxel side-
-chain. Two different enantioselective enzymatic pro-
cesses were developed for the preparation of chiral C-13
paclitaxel side-chain synthon (47,48). In one process, the
enantioselective microbial reduction of 2-keto-3-(N-ben-
zoylamino)-3-phenyl propionic acid ethyl ester 39 to
yield (2R,3S)-(-)-N-benzoyl-3-phenyl isoserine ethyl ester
40 Scheme 9A was demonstrated (47). Hansenula poly-
morpha SC 13865 and Hansenula fabianii SC 13894 cata-
lyzed the enantioselective reduction of ketone 39 to the
(2R,3S)-ethyl ester 40 in greater than 80 % reaction yield
and greater than 94 % e.e. in a preparative-scale biore-
duction using cell suspensions in independent experi-
ments. A 20 % yield of undesired anti-diastereomers
content was obtained with H. polymorpha SC 13865 com-















































































































Scheme 8. (A) Enzymatic hydrolysis of C-13 side-chain of taxanes by C-13 taxolase from Nocardioides albus SC 13911. (B) Enzymatic
hydrolysis of C-10 acetate of taxanes and baccatin III 37 by C-10 deacetylase from Nocardioides luteus SC 13912. (C) Enzymatic hydro-
lysis of C-7 xylose by C-7 xylosidase from Moraxella sp. 13963
pared with a 10 % yield with H. fabianii SC 13894. A 99 %
e.e. was obtained with H. polymorpha SC 13865 com-
pared with a 94 % e.e. with H. fabianii SC 13894. In a sin-
gle-stage fermentation/bioreduction process (15-L scale),
cells of H. fabianii were grown in a 15-L fermentor for
48 h; the bioreduction process was then initiated by ad-
dition of 30 g of substrate and 250 g of glucose and con-
tinued for 72 h. A reaction yield of 88 % and an e.e. of
95 % were obtained for (2R,3S)-ethyl ester 40.
In an alternate enzymatic resolution process for the
preparation of C-13 paclitaxel side-chain, the enantiose-
lective enzymatic hydrolysis of racemic acetate cis-3-
-(acetyloxy)-4-phenyl-2-azetidinone 41 Scheme 9B to
the corresponding (S)-alcohol 42 and the unreacted de-
sired (R)-acetate 43 was demonstrated (43) by lipase
PS-30 from Pseudomonas cepacia (Amano International
Enzyme Company) and BMS lipase (extracellular lipase
derived from the fermentation of Pseudomonas sp. SC
13856). Reaction yields of greater than 48 % (theoretical
maximum yield 50 %) and e.e. of greater than 99.5 %
were obtained for R-acetate. BMS lipase and lipase
PS-30 were immobilized on Accurel polypropylene (PP)
and immobilized lipases were reused (10 cycles) without
the loss of enzyme activity, productivity or the e.e. of
the product 43 in the resolution process. The enzymatic
process was scaled up to 250-L (2.5 kg of substrate in-
put) using immobilized BMS lipase and lipase PS-30, re-
spectively. From each reaction batch, (R)-acetate 43 was
isolated in mol fraction, x=45 % yield (theoretical maxi-
mum yield 50 %) and 99.5 % e.e. (R)-acetate was chemi-
cally converted to (R)-alcohol 44. The C-13 paclitaxel
side-chain synthon (40 or 44), produced either by the
reductive or resolution process, could be coupled to ba-
cattin III 37 after protection and de-protection to prepare
paclitaxel by semi-synthetic process (49).
Oral taxane
Due to poor solubility of paclitaxel, various groups
are developing water-soluble taxane analogs (50). Tax-
ane 45 Scheme 10A is an anticancer water-soluble tax-
ane derivative given orally, which was as effective as in-
travenous paclitaxel in five tumor models murine M109
lung and C3H mammary 16/C cancer, human A2780
ovarian cancer cells (grown in mice and rats) and HCT/pk
colon cancer. Compound 45 was also active in a hu-
man, hormone-dependent, prostate tumor model, CWR-
-22, and just as effective as antiandrogen chemotherapy
(50).
The enantioselective enzymatic hydrolysis of cis-3-
-(acetyloxy)-4-(1,1-dimethylethyl)-2-azetidinone 46
Scheme 10B to the corresponding undesired (S)-alcohol
47 and unreacted desired (R)-acetate 48 was carried out
using immobilized lipase PS-30 or BMS lipase. Reaction
yields of greater than 48 % and e.e. of greater than 99 %
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Scheme 9. Enzymatic synthesis of C-13 side-chain of paclitaxel 36: (A) Enantioselective microbial reduction of 2-keto-3-(N-benzoyl-
amino)-3-phenyl propionic acid, ethyl ester 39. (B) Enantioselective enzymatic hydrolysis of cis-3-(acetyloxy)-4-phenyl-2-azetidinone
41
were obtained for desired 48. Acetoxy -lactam 48 was
converted to hydroxy -lactam 49 for semisynthesis of
oral taxane 45. Immobilized lipase was reused over
many cycles in this process (51).
The synthesis of oral taxane 45 also required 4,10-
-dideacetyl baccatin 50 Scheme 10C as starting material
for the synthesis of C-4 methylcarbonate derivative of
10-deacetyl-baccatin III 51. A microbial process was de-
veloped for deacetylation of 10-deacetyl-baccatin III 38
to 4,10-dideacetyl-baccatin III 50 using a Rhodococcus sp.
SC 162949 isolated from soil using an enrichment cul-
ture technique (52).
Retinoid Receptor Gamma Specific Agonists
A number of studies have demonstrated that reti-
noids (vitamin A derivatives) are essential for normal
growth, vision, tissue homeostasis, and reproduction
(53,54). Retinoic acid and its natural and synthetic ana-
logs (retinoids) exert a wide variety of biological effects
by binding to or activating a specific receptor or sets of
receptors (55). They affect cellular growth and differenti-
ation and are promising drugs for the treatment of can-
cers (56). A few retinoids are already in clinical use for
the treatment of dermatological diseases such as acne
and psoriasis (57). (R)-3-fluoro-4-hydroxy-(5,6,7,8-tetra-
hydro-5,5,8,8-tetramethyl-2-naphthalenyl)-acetylamino-
benzoic acid 52 Scheme 11 is a retinoic acid receptor
gamma-specific agonist potentially useful as a dermato-
logical and anticancer drug (58).
The chiral intermediate ethyl-2-(R)-hydroxy-2-(1’,2’,3’,
4’-tetrahydro-1’,1’,4’,4’-tetramethyl-6’-naphthalenyl)acetate
53 and the corresponding acid 54 were prepared as inter-
mediates in the synthesis of the retinoic acid receptor
gamma-specific agonist 52 (59). Enantioselective microbial
reduction of ethyl-2-oxo-2-(1’,2’,3’,4’-tetrahydro-1’,1’,4’,4’-
-tetramethyl-6-naphthalenyl) acetate 55 to alcohol 53 was
carried out using Aureobasidium pullulans SC 13849 in 98
% yield and with an e.e. of 96 % (59). Among microor-
ganisms screened for the reduction of 2-oxo-2-(1’,2’,3’,4’-
-tetrahydro-1’,1’,4’,4’-tetramethyl-6’-naphthalenyl)acetic
acid 56 to hydroxy acid 54, Candida maltosa SC 16112 and
two strains of Candida utilis (SC 13983, SC 13984) gave
greater than 53 % reaction yields with greater than 96 %
e.e. At the end of the reaction, hydroxyester 53 was ad-
sorbed onto XAD-16 resin and, after filtration, recovered
in 94 % yield from the resin with acetonitrile extraction.
The recovered (R)-hydroxyester 53 was treated with Chi-
razyme L-2 or pig liver esterase to convert it to the corre-
sponding (R)-hydroxyacid 54 in quantitative yield. The
enantioselective microbial reduction of keto amide 57 to
the corresponding (R)-hydroxyamide 58 by A. pullulans
SC 13849 was also demonstrated (59).
Anti-Alzheimer’s Drugs
Resolution of racemic secondary alcohols
(S)-2-Pentanol 59 and (S)-heptanol 61 Scheme 12A
are intermediates in the synthesis of several potential
anti-Alzheimer's drugs that inhibit synthesis and release


























































































Scheme 10. (A) Enzymatic synthesis of C-13 side-chain 49 of orally active taxane 45. (B) Enantioselective enzymatic hydrolysis of
cis-3-acetyloxy-4-(1,1-dimethylethyl)-2-azetidinone 46. (C) Enzymatic C-4 deacetylation of 10-deacetyl-baccatin III 38
of -amyloid peptide (60,61). The enzymatic resolution
of racemic 2-pentanol and 2-heptanol by lipase B from
Candida antarctica has been demonstrated (62). Commer-
cially available lipases were screened for the enantiose-
lective acetylation of racemic 2-pentanol in hexane in the
presence of vinyl acetate as an acyl donor.
C. antarctica lipase B efficiently catalyzed this reac-
tion, giving yields of 49 % (theoretical maximum yield
50 %) and 99 % e.e. for (S)-2-pentanol. In a preparative-
-scale acetylation (100 g of input), 44.5 g of (S)-2-pentanol
was isolated with an e.e. of 98 %. Among the acylating
agents tested, succinic anhydride was best due to easy
recovery of the (S)-2-pentanol at the end of the reaction.
Using 0.68 mol-equivalent of succinic anhydride Scheme
12A and 13 g of lipase B per kg of racemic 2-pentanol,
which was present as both substrate and solvent, a reac-
tion yield of mol fraction x=43 % and an e.e. of greater
than 98 % were obtained for (S)-2-pentanol. The resolu-
tion of 2-heptanol was also carried out using lipase B
under similar conditions to give a reaction yield of mol
fraction x=44 % and an e.e. of greater than 99 % of (S)-2-
-heptanol, isolated in 40 % overall yield.
In an alternative approach, the enantioselective re-
duction of 2-pentanone 63 to the corresponding (S)-2-
-pentanol Scheme 12B was demonstrated for Glucono-
bacter oxydans. Using Triton X-100 treated cells of G.










































Scheme 11. Enzymatic synthesis of chiral synthons for the retinoid receptor gamma specific Agonist 52: (A) Enantioselective micro-
bial reduction of ethyl 2-oxo-2-(1’,2’,3’,4’-tetrahydro-1’,1’,4’,4’-tetramethyl-6’-naphthalenyl) acetate 55 to (R)-hydroxy ester 53. (B)
Enantioselective microbial reduction of 2-oxo-2-(1’,2’,3’,4’-tetrahydro-1’,1’,4’,4’-tetramethyl-6’-naphthalenyl) acetate 56 to (R)-hydroxy










































Scheme 12. (A) Synthesis of chiral intermediates for anti-Alzheimer's drugs: enzymatic resolution of racemic 2-pentanol 59 and
2-heptanol 61 by Candida antarctica lipase. (B) Enantioselective microbial reduction of 2-pentanone 63 to (S)-2-pentanol
oxydans, preparative scale reduction of 2-pentanone was
carried out and 1.06 kg of (S)-2-pentanol was prepared
(63).
Enzymatic Reduction of 5-Oxohexanoate and
5-Oxohexane nitrile
Ethyl-(S)-5-hydroxyhexanoate 65 and (S)-5-hydroxy-
hexane nitrile 67 Scheme 13A are key chiral intermedi-
ates in the synthesis of several pharmaceuticals. Both
chiral compounds have been prepared by enantioselec-
tive reduction of ethyl-5-oxohexanoate 64 and 5-oxohe-
xane nitrile 66 by Pichia methanolica SC 16116. Reaction
yields of 80–90 % and e.e.’s greater than 95 % were ob-
tained for each chiral compound. In an alternate approach,
the enzymatic resolution of racemic 5-hydroxyhexane
nitrile 67 Scheme 13B by enzymatic succinylation was
demonstrated using immobilized lipase PS-30 to obtain
(S)-5-hydroxyhexane nitrile 67 in 35 % yield (maximum
yield is 50 %). (S)-5 Acetoxyhexane nitrile 68 was pre-
pared by enantioselective enzymatic hydrolysis of race-
mic 5-acetoxyhexane nitrile by Candida cylindracea lipase.
A reaction yield of 42 % and an e.e. of greater than 99 %
were obtained (64).
Enantioselective Microbial Reduction of
Substituted Acetophenone
The chiral intermediate ethyl-(S)-1-(2'-bromo-4'-flu-
orophenyl)ethanol 70 Scheme 14A was prepared by
the enantioselective microbial reduction of 2-bromo-
-4-fluoro acetophenone 69 (65). Organisms from the gen-













































Scheme 13. (A) Synthesis of chiral intermediates for anti-Alzheimer's drugs: enantioselective microbial reduction of ethyl-5-oxo-























Scheme 14. Synthesis of chiral intermediates for anti-Alzheimer's drugs: (A) Enantioselective microbial reduction of 2-bromo-4-flu-
oro acetophenone 69. (B) Enantioselective microbial reduction of methyl-4-(2'-acetyl-5'-fluorophenyl) butanoate 71
era Candida, Hansenula, Pichia, Rhodotorula, Saccharomyces
and Sphingomonas and baker's yeast reduced 69 to 70 in
greater than 90 % yield and 99 % e.e. In an alternative
approach, the enantioselective microbial reduction of
methyl-, ethyl- and t-butyl-4-(2'-acetyl-5'-fluorophenyl)
butanoates 71, 73, and 75 Scheme 13B, respectively,
was demonstrated using strains of Candida and Pichia.
Reaction yields of 40–53 % and e.e.’s of 90–99 % were
obtained for the corresponding (S)-hydroxy esters 72,
74, and 76. The reductase that catalyzed the enantiose-
lective reduction of keto esters was purified to homoge-
neity from cell extracts of Pichia methanolica SC 13825. It
was cloned and expressed in Escherichia coli and recom-
binant cultures were used for the enantioselective reduc-
tion of the keto-methyl ester 71 to the corresponding
(S)-hydroxy methyl ester 72. On preparative scale, a re-
action yield of 98 % and an e.e. of 99 % were obtained
(65).
Melatonin Receptor Agonist
Enantioselective enzymatic hydrolysis of
1-2’,3’-dihydro benzo(b)furan-4’-yl-1,2-oxirane
Epoxide hydrolase catalyzes the enantioselective hy-
drolysis of an epoxide to the corresponding enantiome-
rically enriched diol and unreacted epoxide (66,67). The
(S)-epoxide 77 Scheme 15A is a key intermediate in the
synthesis of a number of prospective drug candidates
(68). The enantiospecific hydrolysis of the racemic
1-2’,3’-dihydro benzo(b)furan-4’-yl-1,2-oxirane 77 to the
corresponding (R)-diol 78 and unreacted S-epoxide 77
was demonstrated by Goswami et al. (69). Among cul-
tures evaluated, two Aspergillus niger strains (SC 16310,
SC 16311) and Rhodotorula glutinis SC 16239 selectively
hydrolyzed the (R)-epoxide, leaving behind the (S)-epo-
xide 77 in greater than 95 % e.e. and 45 % yield (maxi-
mum yield is 50 %). Solvents had significant effects on
both the extent of hydrolysis and the e.e. of unreacted
(S)-epoxide 77. Most solvents gave a lower e.e. product
and slower reaction rate than those of reactions without
any solvent supplement. MTBE (15 % volume fraction)
gave a reaction yield of 45 % (theoretical maximum
yield 50 %) and an e.e. of 99.9 % for unreacted (S)-epo-
xide 77.
Biocatalytic Dynamic Kinetic Resolution of
(R,S)-1-2´,3´dihydroenzo(b)furan-4´-yl-
-ethane-1,2-diol
Most commonly used biocatalytic kinetic resolutions
of racemates often provide compounds with high e.e.,
however, the maximum theoretical yield of product is
only 50 %. In many cases, the reaction mixture contains
an approximately 50:50 mixture of reactant and product.
The reactant and product often possess only slight dif-
ferences in physical properties (e.g. a hydrophobic alco-
hol and its acetate), and thus separation may be very
difficult. These issues with kinetic resolutions can be ad-
dressed by employing a »dynamic kinetic resolution«
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Scheme 15. (A) Synthesis of chiral intermediates for a melatonin receptor agonist: enantioselective microbial hydrolysis of racemic
epoxide 77 to the corresponding (R)-diol 78 and unreacted (S)-epoxide 77. (B) Stereoinversion of racemic diol 78 to (S)-diol 78 by
Candida boidinii and Pichia methanolica
process involving a biocatalyst or biocatalyst with me-
tal-catalyzed in situ racemization (70,71).
(S)-1-2´,3´-dihydrobenzo(b)furan-4´-yl-ethane-1,2-diol
78 Scheme 15B is a potential precursor of (S)-epoxide
77 (68). The dynamic kinetic resolution of the racemic
diol 78 to the (S)-enantiomer 78 has been demonstrated
(72) by strains of Candida boidinii, Pichia methanolica, and
Hansenula polymorpha. During biotransformation, the rel-
ative proportion of (S)-diol 78 increased with time and,
at the end of one week, the e.e. obtained with these mi-
croorganisms was in the range of 87–100 % (yield 60–75
%). A new compound was formed during these biotrans-
formations and was identified as the hydroxy ketone 79.
The area of the HPLC peak for hydroxy ketone first in-
creased with time, reached a maximum, and then de-
creased, as expected for the proposed dynamic kinetic
resolution pathway. C. boidinii SC 13822, C. boidinii SC
16115, and P. methanolica SC 13860 transformed the ra-
cemic diol 78 in 3–4 days to (S)-diol 78 in yields of 62–75
% and e.e.'s of 90–100 %.
3-Receptor Agonists
3-Adrenergic receptors are found on the cell sur-
face of both white and brown adipocytes and are re-
sponsible for lipolysis, thermogenesis, and relaxation of
intestinal smooth muscle (73). Consequently, several re-
search groups are engaged in developing selective 3
agonists for the treatment of gastrointestinal disorders,
type II diabetes, and obesity (74,75). Three different
biocatalytic approaches for synthesis of chiral intermedi-
ates required for the total synthesis of 3 receptor ago-
nists 80 Scheme 16A have been investigated (76).
Microbial reduction of 4-benzyloxy-3-
-methanesulfonylamino-2'-bromoacetophenone
The microbial reduction of 4-benzyloxy-3-methane-
sulfonylamino-2'-bromoacetophenone 81 Scheme 16B
to the corresponding (R)-alcohol 82 has been demon-
strated (76) using Sphingomonas paucimobilis SC 16113.
The growth of S. paucimobilis SC 16113 was carried out
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Scheme 16. (A) Enzymatic synthesis of chiral synthon for  3-receptor agonist 80. (B) Enantioselective reduction of 4-benzyloxy-
-3-methanesulfonylamino-2’-bromoacetophenone 81 to (R)-alcohol 82. (C) Enantioselective hydrolysis of -methyl phenylalanine
amide 85 and -methyl-4-methoxyphenylalanine amide 86 by amidase. (D) Enantioselective enzymatic hydrolysis of methyl-(4-me-
thoxyphenyl)-propanedioic acid ethyl diester 88 to (S)-monoester 87
in a 750-L fermentor and cells (60 kg) harvested from
the fermentor were used to conduct the biotransforma-
tion in 10-L and 200-L preparative batches. The cells
were suspended in 80 mM potassium phosphate buffer
(pH=6.0) at m/V=20 % (wet cells) concentration, supple-
mented with compound 81 (2 g/L) and glucose (25
g/L), and the reduction was carried out at 37 °C. In
some batches, the fermentation broth was concentrated
3-fold by microfiltration and subsequently washed with
buffer by diafiltration and used directly in the bioreduc-
tion process. In all the batches, reaction yields of greater
than 85 % and e.e.’s of greater than 98 % were obtained.
The isolation of alcohol 82 from the 200-L batch gave
320 g (80 % yield) of product with an e.e. of 99.5 %.
In an alternate process, 200 g of frozen cells of S.
paucimobilis SC 16113 were suspended in 1 L of 80 mM
potassium phosphate buffer (pH=6.0) and supplied with
10 g of substrate adsorbed on 50 g of hydrophobic resin
XAD-16. In this process, an average reaction yield of 85
% and an e.e. of greater than 99 % were obtained for al-
cohol 82. The product formed was adsorbed on to
XAD-16 resin. At the end of the biotransformation, the
reaction mixture was filtered on a 100-mesh (150 m)
stainless steel screen, and the resin retained by the
screen was washed with water. The product was then
desorbed from the resin with acetonitrile and crystal-
lized, giving an overall x=75 % yield and 99.8 % e.e.
Enzymatic resolution of racemic -methyl
phenylalanine amides
The chiral amino acids 83 and 84 Scheme 16C are
intermediates for the synthesis of 3-receptor agonists
(74,75). These are available via the enzymatic resolution
of racemic -methyl phenylalanine amide 85 and -me-
thyl-4-methoxyphenylalanine amide 86, respectively, by
an amidase from Mycobacterium neoaurum ATCC 25795
(76). Wet cells (m/V=10 %) completed reaction of amide
85 in 75 min with a yield of x=48 % (theoretical max. 50
%) and an e.e. of 95 % for the desired (S)-amino acid 83.
Alternatively, freeze-dried cells were suspended in 100
mM potassium phosphate buffer (pH=7.0) at 1 % con-
centration to give complete reaction in 60 min with a
yield of x=49.5 % (theoretical max. 50 %) and an e.e. of
99 % for the (S)-amino acid 83.
Freeze-dried cells of M. neoaurum ATCC 25795 and
partially purified amidase (amidase activity in cell ex-
tracts purified 5-fold by diethyl aminoethyl celluose
column chromatography) were used for the biotransfor-
mation of compound 86. A reaction yield of x=49 % and
an e.e. of 78 % were obtained for the desired product 84
using freeze-dried cells. The reaction was completed in
50 h. Using partially purified amidase, a reaction yield
of x=49 % and an e.e. of 94 % were obtained after 70 h.
Enantioselective hydrolysis of diethyl
methyl-(4-methoxyphenyl)-propanedioate
The (S)-monoester 87 Scheme 16D is a key inter-
mediate for the synthesis of 3-receptor agonists. The
enantioselective enzymatic hydrolysis of diester 88 to
the desired acid ester 87 by pig liver esterase (76) has
been demonstrated. In various organic solvents the reac-
tion yields and e.e. of monoester 87 depended upon the
solvent used. High e.e.’s (>91 %) were obtained with
methanol, ethanol, and toluene as a co-solvent. Ethanol
gave the highest reaction yield (96.7 %) and e.e. (96 %)
for the desired acid ester 87.
The e.e. of the (S)-monoester 87 was increased by
decreasing the temperature from 25 °C to 10 °C, when
biotransformation was conducted in a biphasic system
using ethanol as a co-solvent. A semi-preparative hydro-
lysis (30 g scale) was carried out using 10 % ethanol as a
co-solvent in a 3-L reaction mixture (pH=7.2) at 10 °C
for 11 h. A reaction yield of x=96 % and an e.e. of 96.9 %
were obtained. From the reaction mixture, 26 g (x=86 %
overall yield) of (S)-monoester 87 of 96.9 % e.e. was iso-
lated.
Cholesterol Lowering Agents
Hydroxy methyl glutaryl CoA reductase inhibitors
Reduction of 4-chloro-3-oxobutanoic acid methyl ester
The reduction of 4-chloro-3-oxobutanoic acid methyl
ester 89 to S-(-)-4-chloro-3-hydroxybutanoic acid methyl
ester 90 Scheme 17 has been carried out with cell sus-
pensions of Geotrichum candidum SC 5469. (S)-90 is a key
chiral intermediate in the total chemical synthesis of 91,
a cholesterol antagonist that acts by inhibiting HMG
CoA reductase (77). In the biotransformation process, a
reaction yield of 95 % and e.e. of 96 % were obtained for
(S)-90 by glucose-, acetate- or glycerol-grown cells
(m/V=10 %) of G. candidum SC 5469 at 10 g/L of sub-






















Scheme 17. Synthesis of a chiral synthon for the cholesterol-lowering drug 91: enantioselective microbial reduction of 4-chloro-3-
-oxobutanoic acid methyl ester 89 to (S)-4-chloro-3-hydroxybutanoic acid ester 90
strate input. The e.e. of (S)-90 was increased to 98 % by
heat-treatment of cell-suspensions (55 °C for 30 min)
prior to conducting the bioreduction of 89.
Reduction of ethyl 4-chloroacetoacetate
In an alternate approach, the asymmetric reduction
of ethyl 4-chloroacetoacetate to (S)-4-chloro-3-hydroxy-
butonoate was demonstrated by a secondary alcohol
dehydrogenase (PfODH) from Pichia finlandica. The gene
encoding PfODH was cloned from P. finlandica and
over-expressed in Escherichia coli. Formate dehydro-
genase was used to regenerate cofactor NADH required
for this reaction. The recombinant E. coli, co-expressing
both PfODH and formate dehydrogenase from Mycobac-
terium sp., produced (S)-4-chloro-3-hydroxybutanoate in
98.5 % yield and 99 % e.e. at 32 g/L of substrate input
(78).
Preparation of (R)-4-cyano-3-hydroxybutyrate
An enzymatic process was developed for the prepa-
ration of 4-halo-3-hydroxybutyric acid derivatives by ke-
toreductase-catalyzed conversion of 4-halo-3-ketobutyric
acid derivatives. Thus the genes encoding halohydrin de-
hydrogenase from Agrobacterium tumefaciens, ketoreduc-
tase from Candida magnoliae, glucose dehydrogenase
from Bacillus subtilis and formate dehydrogenase from
Candida boidinii were separately cloned into Escherichia
coli BL21. Each enzyme was produced by fermentation,
isolated and characterized. Then ethyl (R)-4-cyano-3-hy-
droxybutyrate was prepared from ethyl 4-chloroaceto-
acetate by the following procedure. Ethyl 4-chloroaceto-
acetate was incubated at pH=7.0 with ketoreductase and
glucose dehydrogenase and NADP for 40 h to produce
ethyl (S)-chloro-3-hydroxybutyrate. The ethyl (S)-chloro-
-3-hydroxybutyrate was extracted with ethyl acetate,
dried, filtered and concentrated to yield a  97 % pure
ester. The dried ethyl (S)-chloro-3-hydroxybutyrate was
dissolved in phosphate buffer and mixed with halohy-
drin dehalogenase and sodium cyanide at pH=8.0. After
57 h reaction, essentially pure (R)-4-cyano-3-hydroxybu-
tyrate was recovered, which is an intermediate used in
the synthesis of many HMG-CoA reductase inhibitors (79).
Preparation of (R)- and (S)-ethyl-3-hydroxybutyrate
An efficient two-step enzymatic process for produc-
tion of (R)- and (S)-ethyl-3-hydroxybutyrate (HEB) was
developed and scaled-up to a multikilogram scale. Both
enantiomers were obtained at 99 % chemical purity and
over 96 % e.e., with an overall process yield of 73 %.
The first reaction involved an acetylation of racemic
HEB with vinyl acetate for the production of (S)-HEB. In
the second reaction, (R)-enriched ethyl-3-acetoxybuty-
rate (AEB) was subjected to alcoholysis with ethanol to
derive optically pure (R)-HEB. Immobilized Candida an-
tarctica lipase B (CALB) was employed in both stages,
with high productivity and selectivity. The type of bu-
tyric acid ester influenced the enantioselectivity of the
enzyme. Thus, extending the ester alkyl chain from ethyl
to octyl resulted in a decrease in e.e., whereas using
bulky groups, such as benzyl or t-butyl, improved the
enantioselectivity of the enzyme. The immobilized en-
zyme was packed in a column and the reactants were
circulated through the enzyme bed until the targeted
conversion was reached. The desired products were sep-
arated from the reaction mixture in each of the two
stages by fractional distillation. The main features of the
process are the exclusion of solvent (thus ensuring high
process throughput) and the use of the same enzyme for
both the acetylation and the alcoholysis steps to prepare
kilogram quantities of (S)-HEB and (R)-HEB (80).
Enzymatic reduction of 3,5-dioxo-6-(benzyloxy)
hexanoic acid, ethyl ester
The enantioselective reduction of a diketone, 3,5-di-
oxo-6-(benzyloxy) hexanoic acid ethyl ester 92, to (3R,5S)-
-dihydroxy-6-(benzyloxy) hexanoic acid ethyl ester 93a
Scheme 18 has been demonstrated by cell suspensions
of Acinetobacter calcoaceticus SC 13876 (81). Compound
93a is a key chiral intermediate required for the chemi-





































Scheme 18. Synthesis of a chiral synthon for the cholesterol lowering drug 94: enantioselective microbial reduction of 3,5-dioxo-
-6-(benzyloxy) hexanoic acid, ethyl ester 92 to (3R,5S)-dihydroxy-6-(benzyloxy) hexanoic acid, ethyl ester 93a
cal synthesis of 4-4,6(E)-6-4,4-bis-(4-fluorophe-
nyl)-3-(1-methyl-1H-tetrazol-5-yl)-1,3-butadienyl-tetra-
hydro-4-hydroxy-2H-pyren-2-one 94, an anticholesterol
drug that acts by inhibition of HMG CoA reductase (82).
A reaction yield of 85 % and an e.e. of 97 % were ob-
tained using glycerol-grown cells at 2 g/L. Cell extracts
of A. calcoaceticus SC 13876 in the presence of NAD+,
glucose and glucose dehydrogenase reduced 92 to the
corresponding monohydroxy compounds 3-hydroxy-5-
-oxo-6-(benzyloxy) hexanoic acid ethyl ester 96 and 5-
-hydroxy-3-oxo-6-(benzyloxy) hexanoic acid ethyl ester 95.
Both 95 and 96 were further reduced to the (3R,5S)-di-
hydroxy compound 93a by cell extracts. A reaction yield
of 92 % and an e.e. of 98 % were obtained at 10 g/L of
substrate input.
Enzymatic preparation of a 2,4-dideoxyhexose
derivative
The chiral 2,4-dideoxyhexose derivative required for
the HMG CoA reductase inhibitors has also been pre-
pared using 2-deoxyribose-5-phosphate aldolase (DERA).
As shown in Scheme 19, the reactions start with a ste-
reospecific addition of acetaldehyde 97 to a substituted
acetaldehyde to form a 3-hydroxy-4-substituted butyral-
dehyde 98, which reacts subsequently with another ace-
taldehyde to form a 2,4-dideoxyhexose derivative 99.
DERA has been expressed in Escherichia coli (83).
The above process has been improved and opti-
mized for production of key intermediates for the com-
mon chiral side chain of cholesterol-lowering drugs such
as Lipitor (atorvastatin) and Crestor (rosuvastatin). An
improvement of almost 400-fold in volumetric produc-
tivity relative to the published enzymatic reaction condi-
tions has been achieved, resulting in an attractive pro-
cess that has been run on up to a 100-g scale in a single
batch at a rate of 30.6 g L–1h–1. Catalyst load has been
improved by 10-fold as well, from w=20 to 2.0 % DERA.
These improvements were achieved by a combination of
discovery from environmental DNA of DERA with im-
proved activity and reaction optimization to overcome
substrate inhibition. The two stereogenic centers are set
by DERA with enantiomeric excess at greater than 99.9
% and diastereomeric excess at 96.6 %. In addition,
downstream chemical processes have been developed to
convert the enzyme product efficiently to versatile inter-
mediates applicable to preparation of atorvastatin and
rosuvastatin (84).
Calcium Channel Antagonist
Enzymatic synthesis of (3R-cis)-1,3,4,5-tetrahydro-
-3-hydroxy-4-(4-methoxyphenyl)-6-(trifluoromethyl)-2
H-1-benzazepin-2-one
Diltiazem 100 Scheme 20, a benzothiazepinone cal-
cium channel-blocking agent that inhibits influx of extra-
cellular calcium through L-type voltage-operated calcium
channels, has been widely used clinically in the treat-
ment of hypertension and angina (85). Since diltiazem
has a relatively short duration of action (86), an 8-chlo-
roderivative has recently been introduced into the clinic
as a more potent analogue (87). Lack of extended dura-
tion of action and little information on structure-activity
relationships in this class of compounds led Floyd et al.





























































calcium channel blocker 101Diltiazem 100
Scheme 20. Synthesis of chiral synthon for calcium channel blocker 101: microbial reduction of 4,5-dihydro-4-(4-methoxyphenyl)-6-
-(trifluoromethyl)-1H-benzazepin-2,3-dione 103
(88) to prepare isosteric 1-benzazepin-2-ones; this led to
the identification of (cis)-3-(acetoxy)-1-2-(dimethylami-
no)ethyl-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-6-tri-
fluoromethyl)-2H-1-benzazepin-2-one 101 as a longer
lasting and more potent antihypertensive agent. A key
intermediate in the synthesis of this compound was
(3R-cis)-1,3,4,5-tetrahydro-3-hydroxy-4-(4-methoxyphen
yl)-6-(trifluoromethyl)-2H-1-benzazepin-2-one 102. An
enantioselective microbial process Scheme 20 was de-
veloped for the reduction of 4,5-dihydro-4-(4-methoxy-
phenyl)-6-(trifluoromethyl)-1H-1-benzazepin-2,3-dione
103, which exists predominantly in the achiral enol form
in rapid equilibrium with the two enantiomeric keto
forms. Reduction of 103 could give rise to formation of
four possible alcohol stereoisomers. Remarkably, condi-
tions were found under which only the single alcohol
isomer 102 was obtained. Among various cultures eval-
uated, microorganisms from the genera Nocardia, Rhodo-
coccus, Corynebacterium, and Arthobacter reduced com-
pound 103 with 60-70 % conversion. The most effective
culture, Nocardia salmonicolor SC 6310, catalyzed the
bioconversion of 103 to 102 in 96 % reaction yield with
99.8 % e.e. A preparative-scale fermentation process for
growth of N. salmonicolor and a bioreduction process
using cell suspensions of the organism were demonstra-
ted (89).
Asymmetric hydrolysis of 1,4-dihydropyridine diesters
Streptomyces viridosporus A-914 was screened as a
producer of an enzyme that effectively forms chiral in-
termediates of 1,4-dihydropyridine calcium antagonists
(90). The supernatant liquid of the growing culture of
this strain exhibited high activity for enantioselective
hydrolysis of prochiral 1,4-dihydropyridine diesters to
the corresponding (4R) half esters. The responsible en-
zyme (termed DHP-A) was purified to homogeneity
and characterized. Cloning and sequence analysis of the
gene for DHP-A (dhpA) revealed that the enzyme was a
serine protease that is highly similar in both structural
and enzymatic features to SAM-P45. Homologous or he-
terologous expression of dhpA resulted in overproduc-
tion of the enzyme in culture supernatants, with 2.4- to
4.2-fold higher specific activities than in the parent S.
viridosporus A-914 (90).
Enantioselective Enzymatic Cleavage of the
Carbobenzyloxy (Cbz) Group
Amino groups often require protection during syn-
thetic transformations elsewhere in the molecule; at
some point, the protecting group must be removed. En-
zymatic protection and de-protection under mild condi-
tions have been demonstrated previously. Penicillin G
amidase and phthalyl amidase have been used for the
enzymatic de-protection of the phenylacetyl and phtha-
loyl groups from the corresponding amido or imido
compounds (90,91). Acylases have been used widely in
the enantioselective de-protection of N-acetyl-DL-amino
acids (92). Enzymatic de-protection of N-carbamoyl
L-amino acids and N-carbamoyl D-amino acids has been
demonstrated for microbial L-carbamoylases and D-car-
bamoylases, respectively (93,94).
The carbobenzyloxy (Cbz) group is commonly used
to protect amino and hydroxyl groups during organic
synthesis. Chemical de-protection is usually achieved by
hydrogenation with a palladium catalyst (95,96). How-
ever, during chemical de-protection, some groups are
reactive under the hydrogenolysis conditions (e.g. car-
bon-carbon double bonds) or may interfere with hydro-
genolysis (e.g. thiols or sulfides). An enantioselective en-
zymatic de-protection process has been developed that
can be performed under mild conditions without dam-
aging any otherwise susceptible groups in the molecule.
A microbial culture was isolated from soil and identified
as Sphingomonas paucimobilis strain SC 16113; this culture
catalyzed the enantioselective cleavage of Cbz-groups
from various Cbz-protected amino acids (97). Only Cbz-
-L-amino acids were de-protected, giving complete con-
version to the corresponding L-amino acid. Cbz-D-amino
acids gave <2 % reaction yield.
Racemic Cbz-amino acids were also evaluated as sub-
strates for hydrolysis by cell extracts of S. paucimobilis
SC 16113. As anticipated, only the L-enantiomer was hy-
drolyzed, giving the L-amino acids in greater than 48 %
yields and greater than 99 % e.e.’s. The unreacted Cbz-
-D-amino acids were recovered in greater than 48 % yield
and greater than 98 % e.e. (97). Cbz-cleaving enzyme has
been purified and over-expressed in Escherichia coli (98).
Tryptase Inhibitor
(R,S)-N-(t-butoxycarbonyl)-3-hydroxymethylpiperidine
104 Scheme 21 is a key intermediate in the synthesis of
a potent tryptase inhibitor (99). (S)-104 was made from
(R,S)-3-hydroxy methylpiperidine via fractional crystalli-
zation of the corresponding L(-)-dibenzoyl tartarate salt
followed by hydrolysis and esterification (100). Lipase
from Pseudomonas cepacia was the best enzyme for the
stereospecific resolution of R,S-N-(t-butoxycarbonyl)-3-
-hydroxymethylpiperidine 104. (S)-104 was obtained in
16 % yield and greater than 95 % e.e. by hydrolysis of
R,S-acetate by lipase from P. cepacia. Lipase PS-30 also
catalyzed esterification of the (R,S)-N-(t-butoxycarbo-
nyl)-3-hydroxymethylpiperidine 104 with succinic anhy-
dride 105 to yield (R)-N-(t-butoxycarbonyl)-3-hydroxy
methylpiperidine 104 and the (S)-hemisuccinate ester
106, which could be easily separated and hydrolyzed by
base to the (S)-104. The yield and e.e. could be im-
proved greatly by repeating the process. Using the re-
peated esterification procedure, (S)-104 was obtained in
32 % yield (maximum theoretical yield 50 %) and 98.9 %
e.e. (101).
Acyloin and Aldol Condensation
Asymmetric -hydroxyketones (acyloin) are impor-
tant classes of intermediates in organic synthesis due to
their bi-functional aspect, especially having one chiral
center amenable to further modification. Enzyme-medi-
ated acyloin formation could provide an advantageous,
environmentally-friendly method of preparing optically
active asymmetric acyloins (102). Acyloin formations
mediated by yeast pyruvate decarboxylase (103) and
bacterial benzoylformate decarboxylase (104) have been
reported. Though phenylpyruvate decarboxylase (PPD)
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for decarboxylation of phenylpyruvic acid was known
for a long time (102), recently we reported the acyloin
condensation catalyzed by PPD (105). Achromobacter eyry-
dice PPD was used to catalyze the asymmetric acyloin
condensation of phenylpyruvate 107 with various alde-
hydes 108 to produce optically active acyloins PhCH2-
COCH(OH)R 109 Scheme 22. The acyloin condensation
yield decreased with increasing chain length for straight
chain aliphatic aldehydes from 76 % for acetaldehyde to
24 % for valeraldehyde. The e.e.’s of the acyloin prod-
ucts were 87–98 %. Low yields of acyloin products were
obtained with chloro acetaldehyde (13 %) and glyco al-
dehyde (16 %). Indole-3-pyruvate was a substrate of the
enzyme and provided acyloin condensation product 3-hy-
droxy-1-(3-indolyl)-2-butanone 110 with acetaldehyde in
19 % yield. PPD has been purified from Achromobacter
eyrydice. The purified protein was shown to be of 150
kD molecular weight and to consist of two subunits, one
of 90 kD and one of 40 kD (106).
NK1/NK2 Dual Antagonist
Tachykinins are a group of biologically active neu-
ropeptide hormones that are widely distributed through-
out the nervous system. They are implicated in a variety
of biological processes such as pain transmission, inflam-
mation, vasodilatation and secretion (107). The effect of
Tachykinins is modulated via the specific G-protein cou-
pled receptors like NK1 and NK2. Thus non-peptide
NK-receptor antagonists are potentially useful in the
treatment of a variety of chronic diseases including
asthma, bronchospasm, arthritis, and migraine (108,109).
The structure-activity relationship of several non-pep-
tide NK1/NK2 antagonists has led to the discovery of a
new class of oxime-based dual antagonist (110,111),
namely compound 111 Scheme 23. The biological ac-
tivity of 111 resides mainly in the R,R-diastereomers. An
enzymatic process for desymmetrization of the prochiral
diethyl 3-(3’,4’-dichlorophenyl)-glutarate 112 to the cor-





































Scheme 21. Preparation of a chiral synthon for a tryptase inhibitor: enzymatic resolution of racemic (t-butoxycarbonyl)-3-hydroxy-












108 and 109 (R): a (Me), b (Et), c (n-Pr), d (n-Bu), e (PhCH2), f (Ph), g (H),
h (Me(CH2)6), i (Me(CH2)8), j (Me(CH2)10), k (PhCH=CH), l (Br3C), m (Me2CH),







Scheme 22. Enzymatic asymmetric acyloin condensation reactions catalyzed by phenylpyruvate decarboxylase
responding (S)-monoester 113 has been developed using
lipase B from Candida antarctica in either free or immobi-
lized forms. At 100 g/L of substrate input, a reaction
yield of 97 % and e.e. of greater than 99 % were ob-
tained for desired (S)-monoester. The process was scaled
up to produce 200 kg of product in overall 80 % yield
(112). DNA family shuffling was used to create chimeric
lipase B protein with improved activity towards diethyl-
3-(3’,4’-dichlorophenyl)-glutarate. Three homologous li-
pases from Candida antarctica ATCC 32657, Hyphozyma
sp. CBS 648.91 and Cryptococcus tsukubaensis ATCC
24555 were cloned and shuffled to generate a diverse
gene library and, using a high-throughput screening as-
say, a chimeric lipase B protein having 20-fold higher
activity towards substrate was identified (113). The
thermostability of lipase was also improved by directed
evolution (114).
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Biokataliti~ka sinteza kiralnih farmaceutskih me|uprodukata
Sa`etak
U farmaceutskoj industriji sve je va`nija proizvodnja samo jednog enantiomera kao
me|uprodukta u proizvodnji lijekova. Kiralni me|uprodukti i fine kemikalije na visokoj
su cijeni u farmaceutskoj i agrokemijskoj industriji za pripravu lijekova i agrikulturnih
proizvoda. Prikazan je golemi potencijal mikroorganizama za transformaciju sintetskih ke-
mikalija {to imaju kemoselektivnost, regioselektivnost i enantioselektivnost. U radu su opi-
sani biokataliti~ki procesi za sintezu kiralnih farmaceutskih me|uprodukata.
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